Skip to main content
Lung India : Official Organ of Indian Chest Society logoLink to Lung India : Official Organ of Indian Chest Society
letter
. 2020 May 4;37(3):279–281. doi: 10.4103/lungindia.lungindia_242_20

Safety of an immunomodulator Mycobacterium w in COVID-19

Inderpaul Singh Sehgal 1, Ashish Bhalla 2, Goverdhan Dutt Puri 3, Laxmi Narayana Yaddanapudi 3, Mini Singh 4, Pankaj Malhotra 2, Sahajal Dhooria 1, Vikas Suri 2, Ritesh Agarwal 1
PMCID: PMC7353938  PMID: 32367857

Sir,

Coronavirus disease 2019 (COVID-19) pandemic is associated with a high mortality, especially in those with severe pneumonia. Patients with COVID requiring intensive care unit (ICU) admission have higher cytokine levels compared to those who do not need ICU care.[1] Even among patients admitted to ICU, those discharged from hospital had lower cytokine levels compared to those who died.[2] An immunomodulator may thus be of potential benefit in managing these critically ill COVID patients. The Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R) and the World Health Organization have identified adjuvant therapy as one of the key areas of research to save lives of patients infected with COVID-19.[3] A heat-killed Mycobacterium w (Mw), originally developed as an immunomodulator for leprosy, which acts through the toll-like receptors (TLRs) pathway and enhances the host-T cell responses.[4] We have previously shown the benefit of Mw in patients with severe sepsis.[5] Herein, we describe the safety of Mw in four cases of severe COVID treated with this immunomodulator [Table 1].

Table 1.

Details of patients who received Mycobacterium w vaccine along with standard medical care

Days in hospital Patient 1 Patient 2 Patient 3 Patient 4




1 2 3 4 5 6 7 1 2 4 5 6 7 1 2 3 4 7 1 2 3 7
Hemoglobin (g/dL) 13.6 13.2 12.4 12 11.6 11.6 11.8 12.7 12.8 13 13.3 14.5 14.8 12.4 11.8 11.3 10.9 13.3 12.9 13.3 13.4 13
TLC (cells/µL) 15,200 14,800 13,800 14,900 12,900 12,600 8500 14,000 11,500 11,700 12,400 10,700 8600 7000 7500 8900 10,000 6400 4300 6400 5600 4300
Neutrophils (%) 96.6 94.1 95.5 94.9 91.4 91.9 76 90 87.4 80.2 78 79 74 80.6 82.7 82 82 84 80 84.9 81 66
Lymphocytes (%) 2.6 3.7 3.5 3.1 4.3 4.3 13 4 6.2 7.1 7.6 9.7 12 14.6 11.7 14 10.8 10 13.7 10.1 13 24
Eosinophils (%) 0.4 0.3 0.2 0 2.2 1.6 3.2 0.1 1.2 4.7 6.4 5.3 5 0.3 0.9 1.4 2.7 4 0.7 0.7 1.6 2
Platelet count, cells/µL (×109) 510 507 513 528 507 513 532 243 289 381 411 454 537 112 299 247 348 495 189 204 221 289
CRP (mg/L) 251 254 277 176 127 103 29 244 108 77 17.4 10.9 100 176 155 107 18 32 52 55 33
Procalcitonin (ng/mL) 0.02 0.03 - - - - 0.01 0.09 0.07 0.2 - - 0.04 0.08 0.08 - - - - 0.03 - 0.03
FiO2 0.6 (RBM) 0.5 0.3 0.28 0.24 0.24 0.21 0.36 0.36 0.28 0.24 0.21 0.21 0.5 0.4 0.28 0.21 0.28 0.24 0.24 0.21
SpO2 89 94 94 94 95 98 98 93 94 96 94 94 93 85 94 94 94 95 94 94 97 98
PaO2:FiO2 ratio 170 200 250 250 280 300 300 220 280 290 300 330 273 200 220 221 250 300 221 250 263 300
RR 40 35 35 35 30 20 18 35 30 22 20 19 25 35 25 20 20 20 32 25 25 20
D-dimer 3619 1799 1795 2033 1586 - 1081 428 422 333 309 690 710 289 249 317 339 126 127 172 550 590
CKMB 35 65 47 71 44 50
AST (U/L) 207 225 92 110 111 71 76 32 28 27 24 29 36 34 34 43 51 57 43 49 49
ALT (U/L) 236 259 156 156 156 131 125 32 39 34 32 39 26 30 30 36 69 88 54 55 56
SAP (U/L) 97 102 86 100 123 122 115 114 107 96 86 83 82 89 105 125 147 130 43 39 40
S. cr (mg/dL) 1.1 1.2 0.7 0.7 0.7 0.7 0.8 0.7 0.8 0.8 0.8 0.5 0.5 0.5 0.4 0.4 1.2 0.8 0.9 0.9
Albumin (g/dL) 3.2 3.1 2.6 2.6 2.6 2.7 2.7 3.2 3.1 3 2.9 3.22 3.4 3.4 3.3 3 3.3 4 3.8 3.6 3.4
Adverse event due to Mw Mild erythema at injection site None Mild erythema at injection site None

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, CKMB: Creatine kinase–myocardial band, RBM: rebreathing mask, RR: Respiratory rate, SAP: Serum alkaline phosphatase, S. cr: Serum creatinine, SPO2: Peripheral capillary oxygen saturation by pulse oximeter, FiO2: Fraction of oxygen in inspired air, PaO2: Partial pressure of oxygen in arterial blood, TLC: Total leukocyte count, Mw: Mycobacterium w, CRP: C-reactive protein

All the four patients presented with a history of fever, myalgia, and dyspnea and had a history of contact with a patient of COVID-19. At presentation, patients had tachypnea [Table 1] and were hypoxemic at room air. Complete blood count showed neutrophil predominant leukocytosis and lymphocytopenia [Table 1]. The serum D-dimer levels were elevated in all patients at presentation and were >500 ng/mL in one patient. C-reactive protein (CRP) levels were also elevated in all patients, suggesting a hyperinflammatory state. Creatine kinase–myocardial band was elevated in all patients; however, transthoracic echocardiography did not reveal any abnormality. As per our institutional protocol, all patients received standard medical care comprising oral paracetamol (for fever), oral proton-pump inhibitor for stress ulcer prophylaxis (pantoprazole 40 mg/day), and low-molecular-weight heparin for deep venous thrombosis prophylaxis (enoxaparin 1 mg/kg, once daily). Therapeutic anticoagulation (enoxaparin 1 mg/kg, twice daily) was given in patients who had D-dimer levels >500 ng/mL. We used antibiotics (azithromycin or ceftriaxone) if patients had a total leukocyte count of >11,000 cell/μL, procalcitonin >0.5 ng/mL, or if they had hypotension (mean arterial blood pressure <65 mmHg). We did not use hydroxychloroquine in any of these patients. We also used intradermal Mw (0.3 mL/day [0.1 mL contains 0.5 × 10(9) heat-killed Mw] for 3 consecutive days, Immuvac, Cadila Pharmaceuticals, Ahmedabad, India) in addition to standard medical care.

The treatment protocol resulted in clinical and radiological improvement in all the cases [Figure 1]. The CRP levels improved gradually [Figure 2], and all the patients could be successfully managed without the need for mechanical ventilation. Importantly, Mw did not cause any adverse events, similar to our previous experience in patients with severe sepsis.[5]

Figure 1.

Figure 1

Chest radiograph anteroposterior view of one of our patients demonstrating consolidation and infiltrates in the left upper zone at baseline (a) that improved at day 7 of admission to hospital (b)

Figure 2.

Figure 2

Trend of C-reactive protein during hospital stay

Based on our preliminary experience, we believe that adjunctive Mw is safe in patients with severe COVID-19 infection. However, the efficacy needs to be evaluated in a future randomized controlled trial (clinicaltrials.gov: NCT04347174).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES


Articles from Lung India : Official Organ of Indian Chest Society are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES